Bio-Techne director exercises 589 RSUs
BIO-TECHNE Corp (TECH) director Amy E. Herr reported indirect equity compensation activity relating to her significant other.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) director Amy E. Herr reported indirect equity compensation activity relating to her significant other. On 2026-08-15, 589 restricted stock units covering an equal number of common shares were exercised at $0.00 per share, and 213 common shares were delivered or withheld to cover exercise price or tax liability at $72.40 per share. Following these transactions, she holds 2,680 shares of BIO-TECHNE common stock directly and multiple stock option awards, including options over 2,415 shares at $72.05 expiring in 2035 and 3,777 shares at $60.96 expiring in 2035, along with additional indirect option and RSU positions that vest on various future dates.
Insider Trade Summary
589 shares exercised/converted
Exercise
16 txns
Insider
Herr Amy E.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F7, F8 | 118 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F7, F9 | 160 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F7, F11 | 311 | $0.00 | $0.00 |
| Exercise | Common Stock | 589 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 213 | $72.40 | $15K |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F5 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F6 | -- | -- | -- |
| holding | Restricted Stock Units F7, F10 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F12 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 858 contracts for 77 underlying shares (Indirect, By significant other);
Common Stock — 576 shares (Indirect, By significant other);
Stock Option (Right to Buy) — 6,192 contracts (Direct);
Stock Option (Right to Buy) — 14,283 contracts (Indirect, By significant other);
Common Stock — 2,680 shares (Direct)
Footnotes (12)
- F1. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
- F2. Fully vested.
- F3. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
- F4. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
- F5. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- F6. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
- F7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F8. 118 restricted stock units vest on 8/15/2026.
- F9. 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
- F10. 38 restricted stock units vest on 2/3/2027 and 39 restricted stock units vest on 2/3/2028.
- F11. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
Key Figures
RSUs exercised: 589 shares
Shares delivered/withheld for exercise price or tax liability: 213 shares
Code F transaction price: $72.40 per share
+5 more
8 metrics
RSUs exercised
589 shares
Restricted Stock Units converted into common stock on 2026-08-15
Shares delivered/withheld for exercise price or tax liability
213 shares
Code F transaction at $72.40 per share on 2026-08-15
Code F transaction price
$72.40 per share
Common stock used to pay exercise price or tax liability
Direct common stock holding
2,680 shares
BIO-TECHNE common stock held directly after reported transactions
Option position 1
2,415 underlying shares at $72.05
Direct stock option, expiration 2035-02-03
Option position 2
3,777 underlying shares at $60.96
Direct stock option, expiration 2035-10-30
Largest indirect option position
4,472 underlying shares at $66.97
Indirect stock option via significant other, expiration 2027-08-05
Indirect RSU holding
77 underlying shares
Restricted stock units indirectly held, each for one common share
Key Terms
Restricted Stock Units, Stock Option (Right to Buy), exercise price, vest
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with specified exercise price and expiration date"
exercise price financial
"Options list an exercise price such as 72.0500 or 60.9600 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"Options to purchase or restricted stock units vest on specified future dates"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BIO-TECHNE (TECH) director Amy E. Herr report on this Form 4?
Amy E. Herr reported exercise of 589 restricted stock units into common shares and the delivery or withholding of 213 common shares at $72.40 per share to cover exercise price or tax obligations, all held indirectly through her significant other, plus updated option and RSU holdings.
How many BIO-TECHNE (TECH) restricted stock units did Amy E. Herr convert to common stock?
She converted 589 restricted stock units, each representing a contingent right to one BIO-TECHNE common share. These RSUs vest on specified future dates, and the conversion increased indirect common stock exposure while being partly offset by 213 shares delivered or withheld for exercise price or tax obligations.
What are Amy E. Herr’s direct BIO-TECHNE (TECH) common stock holdings after these transactions?
After the reported activity, Amy E. Herr holds 2,680 shares of BIO-TECHNE common stock directly. In addition, she has several option awards over thousands of shares and indirect holdings through her significant other, but only the 2,680 shares are reported as direct ownership.
What stock options did Amy E. Herr report holding in BIO-TECHNE (TECH)?
She reported multiple stock option awards on BIO-TECHNE common stock, including 2,415 underlying shares at $72.05 expiring in 2035 and 3,777 underlying shares at $60.96 expiring in 2035, plus several indirect option positions with exercise prices from $53.60 to $120.46 and staggered expirations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates